StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Free Report) in a report released on Monday morning. The firm issued a hold rating on the medical research company’s stock.
Accelerate Diagnostics Stock Performance
AXDX opened at $1.79 on Monday. Accelerate Diagnostics has a 1 year low of $0.73 and a 1 year high of $6.39. The firm has a 50 day moving average price of $1.75 and a 200 day moving average price of $1.35. The company has a market cap of $39.47 million, a PE ratio of -0.44 and a beta of 0.61.
Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) last issued its earnings results on Thursday, August 8th. The medical research company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.05. The business had revenue of $2.99 million during the quarter, compared to analysts’ expectations of $3.00 million. On average, sell-side analysts predict that Accelerate Diagnostics will post -2.14 earnings per share for the current year.
Institutional Investors Weigh In On Accelerate Diagnostics
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Featured Articles
- Five stocks we like better than Accelerate Diagnostics
- With Risk Tolerance, One Size Does Not Fit All
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Retail Stocks Investing, Explained
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.